Bivalirudin: a direct thrombin inhibitor (Q28192328)

Europe PubMed Central

title

Bivalirudin: a direct thrombin inhibitor (English)

0 references

author name string

Timothy D Gladwell

series ordinal

1

0 references

language of work or name

English

0 references

publication date

January 2002

0 references

published in

Clinical Therapeutics

0 references

volume

24

0 references

issue

1

0 references

page(s)

38-58

0 references

cites work

Unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Protection of factor Xa from neutralization by the heparin-antithrombin complex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Thrombin and antithrombotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

1 reference

7 January 2021

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Anion-binding exosite of human alpha-thrombin and fibrin(ogen) recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence Chemical and13C nuclear-magnetic-resonance studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Clinical outcomes of bivalirudin for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

A comparison of reteplase with alteplase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021

Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985004-4

7 January 2021